文献速递泌尿生殖介入CTMR

将微波消融引入肾脏消融实践:宝贵的经验教训

Introduction of Microwave Ablation Into a Renal Ablation Practice: Valuable Lessons Learned.
PubMed 文献 · AJR Am J Roentgenol · 2018-09-24

回顾性分析2011至2017年26例患者27个cT1肾脏肿块的经皮微波消融,技术成功率为100%,随访未发现局部肿瘤复发,估计3年局部无进展生存率和肿瘤特异性生存率分别为96%和94%,总体并发症率为19.2%,包括一例死亡。作者认为经皮微波消融是cT1肾脏肿块有前景的微创治疗选择,但可发生大出血和泌尿相关并发症,需进一步研究确定最佳患者和肿瘤选择。

要点

  • cT1肾脏肿块经皮微波消融技术成功率为100%,随访未发现局部肿瘤复发。
  • 估计3年局部无进展生存率和肿瘤特异性生存率分别为96%和94%。
  • 总体并发症率为19.2%,其中大出血或泌尿相关并发症(Clavien-Dindo III级或更高)发生率为11.5%,包括一例死亡。

核心结论

  • 经皮微波消融似乎是cT1肾脏肿块有前景的微创治疗选择,但可发生大出血和泌尿相关并发症,需进一步研究确定最佳患者和肿瘤选择。

研究设计与样本

  • 回顾性综述经皮肾脏消融登记数据库,纳入2011年至2017年接受微波消融的26例患者共27个cT1肾脏肿块,平均年龄63.8岁,男性16例(61.5%),平均肿瘤大小2.3±0.8 cm(范围1.1-4.7 cm);以微波消融后即刻增强CT或MRI评估技术成功,并发症采用Clavien-Dindo分类,局部无进展生存率和肿瘤特异性生存率采用Kaplan-Meier法估计。

诊断标准与关键数值

  • 技术成功定义为微波消融后即刻增强CT或MRI显示技术成功,本组技术成功率为100%;24例患者25个肿瘤随访影像3个月或以上(平均20.6±11.6个月),未发现局部肿瘤复发;估计3年局部无进展生存率为96%,估计3年肿瘤特异性生存率为94%。

临床应用与阅片要点

  • 作者认为经皮微波消融是cT1肾脏肿块有前景的微创治疗选择,但可发生大出血和泌尿相关并发症,需进一步研究确定最佳患者和肿瘤选择。

局限性

  • 本研究为回顾性综述。
  • 需进一步研究确定肾脏微波消融的最佳患者和肿瘤选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: The purpose of this study was to evaluate the early outcomes of percutaneous microwave ablation (MWA) for clinical stage T1 (cT1) renal masses when performed within a high-volume ablation practice with critical emphasis on procedural safety.

MATERIALS AND METHODS: A retrospective review of a percutaneous renal ablation registry identified 26 patients with a total of 27 cT1 renal masses treated with MWA between 2011 and 2017. Mean patient age was 63.8 years and 16 (61.5%) patients were male. Mean renal mass size ± SD was 2.3 ± 0.8 cm (range, 1.1-4.7 cm). The main outcome parameters investigated were technical success, local tumor progression, survival rates, and complications. Complications were categorized using the Clavien-Dindo classification system. Rates of local progression-free and cancer-specific survival (PFS and CSS, respectively) were estimated using the Kaplan-Meier method.

RESULTS: Technical success was 100% on contrast-enhanced CT or MRI performed immediately after renal MWA. Twenty-four patients (92%) with 25 tumors had follow-up imaging for 3 months or longer (mean, 20.6 ± 11.6 months), with no local tumor recurrences identified. Estimated 3-year local PFS and CSS were 96% and 94%, respectively. The overall complication rate was 19.2%; two patients (7.7%) experienced minor complications (grade I or II) and three patients (11.5%) experienced major bleeding or urinary-related complications (grade III or higher), including one death.

CONCLUSION: This study suggests that percutaneous MWA is a promising minimally invasive treatment option for cT1 renal masses. Nonetheless, major bleeding and urinary-related complications can occur, and further studies are needed to determine optimal patient and tumor selection for renal MWA.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Thompson SM, Schmitz JJ, Thompson RH, et al. Introduction of Microwave Ablation Into a Renal Ablation Practice: Valuable Lessons Learned. AJR Am J Roentgenol. 2018. PMID: 30247980. doi:10.2214/AJR.18.19775

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。